Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03580655

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Mast Cell Leukemia Clinical Trial

Official title:
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Clinical Trial Summary

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03580655
Study type Interventional
Source Blueprint Medicines Corporation
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 21, 2018
Completion date January 31, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT01807598 - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Phase 2
Terminated NCT00387426 - Sunitinib in Treating Patients With Idiopathic Myelofibrosis Phase 2
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT00006251 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Phase 1/Phase 2
Terminated NCT02415608 - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Phase 2
Active, not recruiting NCT00118352 - Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Phase 2
Completed NCT02561988 - (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Phase 1
Completed NCT01869777 - Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia N/A
Completed NCT01231919 - MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase 1
Completed NCT01273766 - Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Phase 2
Terminated NCT03214666 - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Phase 1/Phase 2
Completed NCT01199562 - Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Completed NCT00014235 - Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies N/A
Completed NCT04695431 - Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Completed NCT00890747 - Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Phase 1
Completed NCT01053494 - Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer N/A
Available NCT05219266 - Managed Access Programs for PKC412, Midostaurin